These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 16790543

  • 21. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S, Schneider L, Farmer M, Kay G, Crook T.
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [Abstract] [Full Text] [Related]

  • 22. [Memantine].
    Molinuevo JL.
    Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
    [Abstract] [Full Text] [Related]

  • 23. Memantine (Namenda, Forest Pharmaceuticals).
    Roman MW.
    Issues Ment Health Nurs; 2009 Mar; 30(3):202. PubMed ID: 19291500
    [No Abstract] [Full Text] [Related]

  • 24. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT, Edwards KR, Zhao Q.
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [Abstract] [Full Text] [Related]

  • 25. Molecule of the month. Memantine hydrochloride.
    Drug News Perspect; 2003 Jul; 16(1):55. PubMed ID: 12682671
    [No Abstract] [Full Text] [Related]

  • 26. A review of the effects of memantine on clinical progression in Alzheimer's disease.
    Wilkinson D.
    Int J Geriatr Psychiatry; 2012 Aug; 27(8):769-76. PubMed ID: 21964871
    [Abstract] [Full Text] [Related]

  • 27. 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.
    Karanian DA, Baude AS, Brown QB, Parsons CG, Bahr BA.
    Hippocampus; 2006 Aug; 16(10):834-42. PubMed ID: 16897723
    [Abstract] [Full Text] [Related]

  • 28. Memantine: a new hope for treatment of Lewy body-related dementias?
    Emre M.
    Lancet Neurol; 2009 Jul; 8(7):594-5. PubMed ID: 19520612
    [No Abstract] [Full Text] [Related]

  • 29. Pathologically activated therapeutics for neuroprotection.
    Lipton SA.
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [Abstract] [Full Text] [Related]

  • 30. Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity.
    Ji W, Zhang Y, Luo J, Wan Y, Liu J, Ge RL.
    Life Sci; 2021 Apr 01; 270():119012. PubMed ID: 33422543
    [Abstract] [Full Text] [Related]

  • 31. [Memantine: from the original brand to generics].
    Titova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Apr 01; 117(10):136-143. PubMed ID: 29171502
    [Abstract] [Full Text] [Related]

  • 32. [Alzheimer dementia. Memantine: value for patient and caregivers].
    MMW Fortschr Med; 2009 Nov 05; 151(45):44-5. PubMed ID: 19960725
    [No Abstract] [Full Text] [Related]

  • 33. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study.
    Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, Lazzeroni L, Rasgon NL.
    Acta Neurol Scand; 2009 Mar 05; 119(3):172-9. PubMed ID: 18705678
    [Abstract] [Full Text] [Related]

  • 34. [Also consider non-cognitive disorders].
    Krankenpfl J; 2005 Mar 05; 43(7-10):211-2. PubMed ID: 16515283
    [No Abstract] [Full Text] [Related]

  • 35. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T.
    Neuropharmacology; 2006 Dec 05; 51(7-8):1181-91. PubMed ID: 17011596
    [Abstract] [Full Text] [Related]

  • 36. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG, Stöffler A, Danysz W.
    Neuropharmacology; 2007 Nov 05; 53(6):699-723. PubMed ID: 17904591
    [Abstract] [Full Text] [Related]

  • 37. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients.
    Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpérovitch A.
    Alzheimer Dis Assoc Disord; 2008 Nov 05; 22(2):125-30. PubMed ID: 18525283
    [Abstract] [Full Text] [Related]

  • 38. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N, Ott BR, Peskind E, Resnick EM.
    Alzheimer Dis Assoc Disord; 2007 Nov 05; 21(1):60-4. PubMed ID: 17334274
    [Abstract] [Full Text] [Related]

  • 39. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM, Boyle LL, Porsteinsson AP.
    Expert Opin Pharmacother; 2007 Feb 05; 8(2):203-14. PubMed ID: 17257090
    [Abstract] [Full Text] [Related]

  • 40. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
    Kato T.
    Nihon Yakurigaku Zasshi; 2004 Sep 05; 124(3):145-51. PubMed ID: 15333987
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.